Journal article
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Abstract
BACKGROUND: The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is unknown. We aimed to assess whether acarbose could reduce the frequency of cardiovascular events in Chinese patients with established coronary heart disease and impaired glucose tolerance, and whether the incidence of type 2 diabetes could be reduced.
METHODS: The Acarbose …
Authors
Holman RR; Coleman RL; Chan JCN; Chiasson J-L; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z
Journal
The Lancet Diabetes & Endocrinology, Vol. 5, No. 11, pp. 877–886
Publisher
Elsevier
Publication Date
11 2017
DOI
10.1016/s2213-8587(17)30309-1
ISSN
2213-8587